Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 52-Week Low – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price hit a new 52-week low during trading on Tuesday. The company traded as low as $19.00 and last traded at $19.34, with a volume of 50939 shares trading hands. The stock had previously closed at $19.31.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CHGCY. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. UBS Group cut shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Chugai Pharmaceutical presently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The company has a 50 day moving average of $21.27 and a two-hundred day moving average of $23.57. The company has a market capitalization of $63.15 billion, a PE ratio of 20.85 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The firm had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. On average, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.